A new opportunity for nanomedicines

2017, Paolini M. et al.

Authors

Marion Paolini1,2, Laurence Poul, PhD1, Audrey Darmon1, Matthieu Germain, PhD1, Agnès Pottier, PhD1, Laurent Levy, PhD1, Eric Vibert, MD, PhD2
1 – Nanobiotix SA, rue de Wattignies, Paris, France
2 – UMR-S 1193 Inserm/University Paris Sud, Centre Hépato-Biliaire, Hôpital Paul Brousse, Villejuif, France

Summary

Nanomedicines are mainly used as drug delivery systems; here we evaluate a new application – to inhibit a drug’s metabolism thereby enhancing its effective dose. Micelles containing the natural furanocoumarin 6′,7′ dihydroxybergamottin (DHB), a known CYP450 inhibitor, were developed to transiently block hepatic CYP450-mediated drug metabolism and increase the bioavailability of the oncology drug docetaxel. Administered in mice 24 h prior to the drug, DHB-micelles enhanced antitumor efficacy in the tumor xenograft models HT-29 and MDA-MB-231, when compared to the drug alone. These DHB-micelles have similar composition to marketed docetaxel–micelles for human use. Despite not being optimized in terms of targeting hepatocytes, they do represent the first injectable example of nanosized metabolism-blocking agents and open the way for further work on such nanomedicines in man.

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.

CloseFermer